34 related articles for article (PubMed ID: 38532575)
21. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
Armitage JO
Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
[TBL] [Abstract][Full Text] [Related]
22. The aggressive peripheral T-cell lymphomas: 2013.
Armitage JO
Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation for T-cell lymphomas.
Perrone G; Corradini P
Semin Hematol; 2014 Jan; 51(1):59-66. PubMed ID: 24468317
[TBL] [Abstract][Full Text] [Related]
24. Prognostic markers in peripheral T-cell lymphoma.
Piccaluga PP; Agostinelli C; Gazzola A; Mannu C; Bacci F; Sabattini E; Pileri SA
Curr Hematol Malig Rep; 2010 Oct; 5(4):222-8. PubMed ID: 20690003
[TBL] [Abstract][Full Text] [Related]
25. How I treat the peripheral T-cell lymphomas.
Moskowitz AJ; Lunning MA; Horwitz SM
Blood; 2014 Apr; 123(17):2636-44. PubMed ID: 24615779
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
27. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
28. Peripheral T-cell lymphomas.
Savage KJ
Blood Rev; 2007 Jul; 21(4):201-16. PubMed ID: 17512649
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
Civallero M; Schroers-Martin JG; Horwitz S; Manni M; Stepanishyna Y; Cabrera ME; Vose J; Spina M; Hitz F; Nagler A; Montoto S; Chiattone C; Skrypets T; Perez Saenz MA; Priolo G; Luminari S; Lymboussaki A; Pavlovsky A; Marino D; Liberati M; Trotman J; Mannina D; Federico M; Advani R
Br J Haematol; 2024 Mar; ():. PubMed ID: 38532575
[TBL] [Abstract][Full Text] [Related]
30. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.
Bellei M; Nabhan C; Pesce EA; Conte L; Vose JM; Foss F; Federico M
Curr Hematol Malig Rep; 2015 Dec; 10(4):448-55. PubMed ID: 26449717
[TBL] [Abstract][Full Text] [Related]
31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
32. The role of high-dose therapy in peripheral T-cell lymphomas.
Reimer P; Rüdiger T; Wilhelm M
Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
[TBL] [Abstract][Full Text] [Related]
33. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
34. Updates in the Treatment of Peripheral T-Cell Lymphomas.
Saleh K; Michot JM; Ribrag V
J Exp Pharmacol; 2021; 13():577-591. PubMed ID: 34188559
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
